Navigation Links
Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
Date:5/2/2011

LONDON, May 3, 2011 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces the issuance of patent 4,705,370, titled "Further Novel Forms of Interfering RNA Molecules," by the Japanese Patent Office.  The issued patent covers aspects of Silence's platform of novel, short interfering RNA (siRNA) molecules containing 2'-O-Methyl structures known as AtuRNAi.  Silence's AtuRNAi molecules offer important advantages over conventional siRNA molecules including increased stability and yield, lower manufacturing costs and the absence of toxic metabolites.  Several therapeutics incorporating the company's AtuRNAi technology are currently being studied in five ongoing clinical trials conducted by Silence and other industry leaders.

"The ability to expand our strong RNAi patent portfolio into a large pharmaceutical market such as Japan represents the latest success in our proactive ongoing intellectual property strategy.  Not only does this milestone offer important protection for our RNAi technology in Japan, but it also provides another critical asset to support our efforts to establish valuable partnerships with leaders in the Japanese pharmaceutical industry," stated Philip Haworth, Ph.D., chief executive officer of Silence Therapeutics.  "We believe that this allowance by the Japanese Patent Office coupled with our broad, global protection offered by our core patents will highlight the value of our RNAi therapeutic technology to those Japanese companies with an interest in this exciting area of medicine."

Silence Therapeutics is executing a proactive strategy to continue to build and strengthen a global, diverse and competitive intellectual property portfolio that provides the Company and its partners with a strong proprietary position in the RNAi therapeutics space.  The Company believes that it will continue to make significant progress in these efforts as it expects additional RNAi
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
2. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
3. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
4. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
5. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
6. Silence Therapeutics Appoints New Vice President of Research
7. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
8. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
9. Cell Therapeutics Retires 7.5% Convertible Senior Notes
10. Talecris Biotherapeutics Announces First Quarter 2011 Results
11. Nektar Therapeutics Reports First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Senior supply chain management executives from over 50 ... of “Reducing Cost, Lead Time, & Defects in the ... the partnership of the Bio Supply Management Alliance ( ... SCMI) of the University of San Diego in ... Institute of Peace and Justice in San Diego, Devendra ...
(Date:7/10/2014)... , July 10, 2014 On ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique project ... project BIOCAD develops a number of innovative drugs based ... diseases. The ceremony took place at the International Exhibition ...
(Date:7/10/2014)... July 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, ... today announced an agreement with Lineagen, Inc., ... Lineagen,s NextStep Dx PLUS.  Lineagen, focused ... neurological disorders, currently offers FirstStep Dx ... service used by healthcare providers as a ...
(Date:7/10/2014)... Calif., July 10, 2014   Ceres, Inc . ... seed company, announced today financial results for the three ... on its business. Ceres reported that the ... product performance this growing season in Brazil, which concluded ... the company,s sorghum evaluation areas for part of the ...
Breaking Biology Technology:Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... in Nature Physics , they used graphene, the world,s ... Graphene is a sheet of carbon atoms arranged in a ... signs of the conventional magnetism usually associated with such materials ... Manchester researchers the Nobel Prize in Physics in 2010. ...
... LONDON, January 6, 2012 The Lancet ... its first app for iPad is now available on the ... app that makes it easier for healthcare professionals (HCPs) to find ... their iPad. , ,"In this new mobile and tablet age, ...
... company developing a revolutionary non-invasive test for the early ... that it has achieved full automation of its Cell-CT™ ... biosignatures from intact cells.  Development of the fully automated ... $2.6 million grant from the National Institutes of Health,s ...
Cached Biology Technology:Graphene reveals its magnetic personality 2The Lancet Makes Research More Accessible for Healthcare Professionals With New App for iPad 2VisionGate Uses $2.6 Million NIH Grant to Achieve Full Automation of Cell-CT™ 3D Imaging System for Early Diagnosis of Cancer 2VisionGate Uses $2.6 Million NIH Grant to Achieve Full Automation of Cell-CT™ 3D Imaging System for Early Diagnosis of Cancer 3VisionGate Uses $2.6 Million NIH Grant to Achieve Full Automation of Cell-CT™ 3D Imaging System for Early Diagnosis of Cancer 4
(Date:7/11/2014)... In addition to the hippocampus, the marginal division ... and memory. What is the impact degree of ... learning and memory function? Yan Yu and his ... China found, using immunofluorescence staining, that substance P ... hippocampus and striatal marginal division of normal rats. ...
(Date:7/11/2014)... let nerve cells send out electrical signals, Johns Hopkins ... that may offer a new way to protect crops ... way. , Their findingthat naturally occurring insect toxins ... a closely related onesuggests that insecticides can be designed ... bees. A summary of the research, led by Frank ...
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... the Entomological Society of America (ESA) features the Linnaean ... a lively question-and-answer, college bowl-style competition on insect facts ... and entertaining component of the ESA Annual Meeting. ... Branches will compete in the national competition this December ...
... Largo, Fla. April 27, 2009 A new study ... for reattaching large sponges that have been dislodged from coral ... of other large sponge species removed by human activities or ... sponge were removed and reattached at Conch Reef off of ...
... 27, 2009) In an in vitro study, led by ... discovered how a protein called SUMO (Small Ubiquitin-related Modifier) ... chromatin to regulate expression of genes. Chromatin is a ... chromosomes. The interaction between SUMO and the enzyme complex ...
Cached Biology News:Entomological Society of America's Linnaean Games teams selected 2Large sponges may be reattached to coral reefs 2SUMO protein guides chromatin remodeler to suppress genes 2
...
... XL provides RS232/Serial data collection and automation ... Complete instrument integration with Microsoft Excel ... balances, pH meters, titrators, density meters, force ... and serial instruments can be added and ...
DNA sequencing - plasmids or PCR fragments, 3-7 working days service....
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Biology Products: